Saneca Pharma strengthens senior team
Jeremy Drummond, sales and marketing director, Saneca Pharma.
Jeremy Drummond will focus on growing the CDMO’s API and finished dosage form development and manufacturing business in Europe and North America.
Slovakia-based CDMO, Saneca Pharma, has added senior talent to its team to position the company for its next phase of growth.
With a background in the pharmaceutical contract services industry spanning over 20 years, Jeremy Drummond joins the CDMO as sales and marketing director.
Jeremy will be focused on growing Saneca Pharma’s API and finished dosage form development and manufacturing business in Europe and North America.
Juraj Kubáň also joins the CDMO in the role of project development manager. With a background in pharmaceutical project management and a PhD in organic chemistry, Juraj will assist Saneca Pharma’s customers with the efficient transfer of products from API through to finished dosage form.
Anthony Sheehan, CEO at Saneca Pharma said: “Our site has a strong big pharma heritage, with over 70 years’ expertise in producing APIs and finished dosage forms. Following the company’s transition to CDMO, a key focus is to ensure the market and customers understand what makes the Saneca Pharma offering different.
“Adding the likes of Jeremy and Juraj to our senior management team underlines our commitment to be the outsourcing partner of choice for pharmaceutical companies in need of a technically agile and responsive CDMO. Both have exceptional experience in the contract services sector that will help ensure we compete with the biggest CMOs and CDMOs across the globe.”
From its site in Hlohovec, Slovakia, Saneca Pharma provides full service development and manufacturing capabilities for APIs and finished dosage forms. With particular expertise in controlled substances, the CDMO can produce opiate products from ‘farm to pharmacy’, simplifying the supply chain for its customers.
Jeremy said: “As the biggest pharmaceutical company in Slovakia with significant growth plans for the contract manufacturing business, it’s an exciting time to join Saneca. We are well positioned to offer a fully integrated drug development, manufacturing and supply service thanks to the range of technologies and quality of pharmaceutical expertise found on our site.
“We expect to experience steady growth in the coming months as our team has the technical agility to handle multi-step products, complex molecules, novel release mechanisms and patient compliance challenges; services that are in demand in today’s market.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.